Loading clinical trials...
Loading clinical trials...
A Phase 3b, Randomized, Controlled Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer
Conditions
Interventions
Nadofaragene Firadenovec
Locations
79
United States
University of South Alabama (USA) Health System - USACM
Mobile, Alabama, United States
Urology Associates of Mobile
Mobile, Alabama, United States
Mayo Clinic Arizona
Phoenix, Arizona, United States
Urology Associates of Central California
Fresno, California, United States
American Institute of Research
Los Angeles, California, United States
Urology Center of Southern California
Murrieta, California, United States
Start Date
October 1, 2024
Primary Completion Date
June 30, 2028
Completion Date
June 30, 2031
Last Updated
March 30, 2026
Lead Sponsor
Ferring Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions